CombiGene AB (publ) reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was SEK 11.4 million. Net loss was SEK 2.68 million compared to SEK 10.86 million a year ago. Basic loss per share from continuing operations was SEK 0.14 compared to SEK 0.95 a year ago. Diluted loss per share from continuing operations was SEK 0.14 compared to SEK 0.95 a year ago.